Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2019–2023

IMPROVE-PD · Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2019-01-01 → 2023-06-30
EU contribution
€3,970,006
Participants
22
Scheme
MSCA-ITN

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Results in brief

Identification and Management of Patients at Risk – Outcome and Vascular Events inPeritoneal Dialysis

Chronic kidney disease (CKD) afflicts 8% of the European population and increase risks of infections, cardiovascular disease (CVD) and death. It might progress to end-stage renal disease, prevalent in 250,000 people in Europe, from infants to geriatrics, that depend on a life-saving renal replacement therapy such as peritoneal dialysis (PD). During PD, a fluid is instilled into the peritoneal cavity so ultrafiltration (UF) and diffusion occur across the peritoneal membrane (PM) to eliminate waste materials and water from the body. Although PD offers economic and performance benefits over haemodialysis (HD), both therapies accelerate atherosclerosis and CVD. Improved understanding of the molecular mechanisms involved in inflammation, and their connection with CVD will help in the design of interventions to reduce PD-related complications. Inter-sectoral research and well-trained researchers with amultidisciplinary skills are crucial to drive improvements in PD therapy. A risk-adjusted individualized PD approach is also crucial. IMPROVE-PD consortium was born to allow close collaboration between industrial and academic sectors, working in partnership with patients and public to achieve these ambitious targets. IMPROVE-PD aimed to reduce CVD and mortality in PD patients by enabling tailored approaches targeted to the individual characteristics of the patient. To achieve this, the consortium worked on 3 different scientific work packages (WP), aiming at: 1. “Identifying the patient at risk who will benefit from individualizing therapy” 2. “Understanding the patient at risk” 3. “Early phase studies of novel anti-inflammatory therapies in PD” Throughout these years, the consortium has impacted on the social, economic and scientific areas, strongly contributing with a large amount of new knowledge to improve patients’ quality of life. It combined PD registries and biobanks, and innovative experimental models to delineate the role of local and systemic, metabolic and immune system-mediated responses on patient outcome. Based on predictive algorithms and pathophysiological markers signatures, therapeutic actions resulted in improvement and personalisation of PD therapy.

Data: CORDIS, © European Union

Project objective

Peritoneal dialysis (PD) is an underused life saving renal replacement therapy for end-stage kidney disease. Nevertheless, PD patients remain at high risk for poor outcome, most notably excessive risk of cardiovascular disease. There is an unmet need for a risk-adjusted individualized PD approach. The IMPROVE-PD consortium provides 15 Early Stage Researchers (ESRs) in 11 partner institutes located in 7 different countries a state-of-the-art, multidisciplinary and intersectoral pan- European training programme including input from academic, clinical and industrial stakeholders. Network-wide and local training activities, individual research projects, intersectoral secondments and short laboratory visits will provide key generic skills and will prepare ESRs for future roles as highly skilled researchers in Europe. Well-phenotyped patient cohorts, and novel experimental models and techniques will be exploited by the ESRs, mentored by an excellent supervisory team, to improve future management of the PD patient at risk. This joint effort encourages productive collaboration between industrial and academic sectors though integrated projects and shared goals. Key findings will be communicated to a broad range of stakeholders through state of the art methods. IMPROVE-PD will give rise to a new generation of experts in PD with outstanding interdisciplinary research skills, intersectoral understanding and with perspective to pursue their careers in this scientific and industrial field. It will enable timely identification of the PD patient at high risk for adverse outcome, develop understanding of underlying pathomechanisms, and within an iterative process between research groups foster the development of innovative approaches to individualized treatment by targeting revealed pathomechanisms. Through these approaches, the ITN will achieve refinement of PD fluids, PD therapy and cardiovascular risk reduction.

Original text from CORDIS.

Participants

  • AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS · MadridCoordinatorSpain
  • Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry · AdelaideAustralia
  • BAXTER MEDICAL PRODUCTS GMBH · WienAustria
  • CARDIFF UNIVERSITY · CARDIFFUnited Kingdom
  • EPSILON 3 GMBH · WienCity levelAustria
  • EuroPD eV · BerlinGermany
  • FRESENIUS NETCARE GMBH · Bad HomburgGermany
  • FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSIATRIO LA PAZ · MadridSpain
  • INSTITUT DE RECERCA BIOMEDICA DE LLEIDA FUNDACIO DOCTOR PIFARRE · LleidaSpain
  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisFrance
  • Kidney Research UK · PeterboroughUnited Kingdom
  • MEDIZINISCHE UNIVERSITAET WIEN · WienAustria
  • NIERSTICHTING NEDERLAND · BussumNetherlands
  • NORTH BRISTOL NATIONAL HEALTH SERVICE TRUST · BristolUnited Kingdom
  • STICHTING AMSTERDAM UMC · AmsterdamNetherlands
  • UNIVERSIDAD AUTONOMA DE MADRID · MadridSpain
  • UNIVERSITATSKLINIKUM HEIDELBERG · HeidelbergGermany
  • UNIVERSITE CATHOLIQUE DE LOUVAIN · LOUVAIN LA NEUVEBelgium
  • UNIVERSITEIT GENT · GentBelgium
  • UNIVERSITY OF KEELE ROYAL CHARTER · KeeleUnited Kingdom
  • UNIWERSYTET MEDYCZNY IM KAROLA MARCINKOWSKIEGO W POZNANIU · POZNANPoland
  • ZYTOPROTEC GMBH · WienAustria

Links

Data: CORDIS, © European Union